Please login to the form below

Not currently logged in
Email:
Password:

Dr Ameet Nathwani moves from Novartis to Sanofi

He becomes executive vice president, group chief medical officer

Sanofi Dr Ameet NathwaniSanofi has appointed Dr Ameet Nathwani to the newly-elevated position of executive vice president, group chief medical officer and member of its executive committee.

Dr Nathwani will take up the role on 1 May, succeeding Dr Paul Chew who has served as senior vice president, chief medical officer since January 2013 and plans to retire later this year.

Oliver Brandicourt, Sanofi's chief executive officer, said: “Our industry is experiencing increased pressure to support reimbursement with customized data from real-world evidence, demonstrate ongoing benefit-risk of registered products through continuous scientific data generation, and ensure that data are effectively and transparently communicated.

“In order to shape Sanofi's strategy and enhance our world class medical capabilities to address these challenges we have elevated the role of chief medical officer to the executive committee.”

As chief medical officer Dr Nathwani will be responsible for the pharmaceutical firm's medical, patient safety and medical quality assurance as well as the transparency and compliance standards of Sanofi's work with healthcare providers, patients and medical organisations.

He brings over 20 years of pharmaceutical experience to the role, having first joined Glaxo Group Research in 1994 and held increasingly senior positions during his time at the group, including vice president of cardiovascular clinical development.

Dr Nathwani joined Novartis in 2004 as its senior vice president and global development head of the cardiovascular and metabolic franchise. He currently serves as Novartis' global head of medical affairs.

Brandicourt added: “We are very happy to count on Ameet's strong experience in both development and medical fields.

“I would also like to take this opportunity to thank Paul Chew for his many valuable contributions to Sanofi. During his long-standing career, Paul has been a highly valued and key Sanofi leader who has strong medical leadership.”

24th March 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics